Bio-Rad Laboratories
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span ...
Latest News
3 days ago · globenewswire.com
BIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ETHOLMDEL, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, today announced its third quarter (Q3'26) and nine-month (9M'26) results for the period ended September 30, 2026.
4 days ago · globenewswire.com
BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATEKUALA LUMPUR, MALAYSIA, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS; "BGMS" or the "Company"), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced third quarter financial results and provided a business update.
5 days ago · globenewswire.com
BIO-key Enters Gaming / Hospitality Market with Contract from Major U.S. Casino ResortBIO-key entered gaming & hospitality market with contract from major U.S. casino resort to deploy PortalGuard® IAM platform and Identity-Bound Biometrics.
6 days ago · seekingalpha.com
Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference TranscriptBio-Rad Laboratories, Inc. ( BIO ) 2026 UBS Global Healthcare Conference November 10, 2026 8:00 AM EST Company Participants Roop Lakkaraju - Executive VP & CFO Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division Welcome Roop Lakkaraju, EVP and Chief Financial Officer of Bio-Rad. Roop, thank you for being here this morning.
6 days ago · globenewswire.com
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Al
8 days ago · zacks.com
Why Bio-Rad (BIO) International Revenue Trends Deserve Your AttentionExamine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
12 days ago · globenewswire.com
Medicus Pharma to Present at BIO-Europe 2026Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs
12 days ago · marketbeat.com
What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings CallBio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset weakness in parts of its life sciences business.
12 days ago · seekingalpha.com
Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call TranscriptBio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
12 days ago · zacks.com
Bio-Rad Laboratories (BIO) Q3 Earnings Top EstimatesBio-Rad Laboratories (BIO) came out with quarterly earnings of $2.65 per share, beating the Zacks Consensus Estimate of $2.61 per share. This compares to earnings of $2.26 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BIO